What UK pre-hospital providers use intranasal analgesia? A survey of its current and planned use by air ambulance services in the United Kingdom
© Pascoe et al; licensee BioMed Central Ltd. 2014
Published: 7 July 2014
Intranasal analgesia (INA) has been used for many years as an alternative method of delivering pain relief in-hospital, especially in paediatric populations [1, 2]. London’s Air Ambulance (LAA) is considering introducing and INA standard operating procedure (SOP) to complement their current methods of delivering analgesia pre-hospital. Little data exists on the current use of pre-hospital INA in the United Kingdom (UK). We aimed to determine what pre-hospital providers in the United Kingdom currently use or plan to introduce INA and what agents they are using.
Do you currently have an SOP for INA?
If so which agents do you use?
If not do you have plans to introduce its use in the near future?
The data was collated in a Microsoft Excel spreadsheet and basic statistical analysis carried out.
Data was provided by 16 of the 19 UK services contacted. 8 (50%) currently use INA, 5 in paediatrics and 3 in paediatrics and adults. No provider used INA solely for adults. 4 (25%) are currently planning to introduce INA. 4 (25%) of the services contacted have no plans to introduce INA. 6 providers used Diamorphine, 1 ketamine and 1 diamorphine and ketamine.
75% of the UK air ambulance providers who responded either currently use or plan to introduce INA in the near future. This represents a large pool of clinical experience and expertise and should be used to help guide LAA in their decision to introduce INA to their current analgesia SOPs.
- Kendall JM, Reeves BC, Latter VS: Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. BMJ. 2001, 322: 261-265. 10.1136/bmj.322.7281.261.PubMed CentralView ArticlePubMedGoogle Scholar
- Guidelines for the management of pain in children. College of Emergency Medicine. 2004Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.